GSK’s Blenrep has pivotal clinical trial results showing the multiple myeloma therapy reduced the risk of disease progression or death by nearly 50%. The results were presented Sunday during the annual meeting of the America Society of Clinical Oncology.

The post GSK’s Quest to Bring Myeloma Drug Back to the Market Stops for a Data Drop at ASCO appeared first on MedCity News.

AstraZeneca’s Tagrisso and Imfinzi helped patients live longer in separate pivotal clinical trials evaluating the drugs in two different types of lung cancer. The results will be presented Sunday during the annual meeting of the American Society of Clinical Oncology.

The post At ASCO, AstraZeneca Adds Data Supporting Expanded Use of Its Drugs in Lung Cancer appeared first on MedCity News.

Gilead Sciences reported Trodelvy’s Phase 3 test in metastatic urothelial cancer fell short of showing a statistically significant benefit on the overall survival main goal. The antibody drug conjugate had received accelerated FDA approval for this type of cancer in 2021.

The post Gilead Sciences ADC Flunks Its Confirmatory Test in Advanced Bladder Cancer appeared first on MedCity News.

During the annual meeting of the American Society of Clinical Oncology, a cell therapy posted clinical data that could broaden its use in multiple myeloma. In other developments, the class of drugs called ADCs continue to make progress and a novel brain cancer drug has Phase 3 data that support its use as a new treatment option.

The post ASCO Recap: Multiple Myeloma Moves, ADC Advances & Brain Cancer Progress appeared first on MedCity News.

The HER2 protein targeted by the approved cancer drug Enhertu is found on a wide range of tumors. Interim Phase 2 data reported at the annual meeting of the American Society of Clinical Oncology suggest the AstraZeneca and Daiichi Sankyo drug has potential to treat many of these cancers.

The post AstraZeneca, Daiichi Drug Shows Signs It Could Treat a Wide Range of Tumor Types appeared first on MedCity News.

In a confirmatory Phase 3 test of ImmunoGen’s Elahere, the ovarian cancer drug handily beat chemotherapy with results that clinicians say could make the treatment the new standard of care for certain patients. The data were presented during the annual meeting of the American Society of Clinical Oncology.

The post How Data for ImmunoGen Drug Could Change the Way Doctors Treat Ovarian Cancer appeared first on MedCity News.

A Servier drug candidate acquired as part of a $1.8 billion deal kept a particular type of brain cancer from progressing in a Phase 3 clinical trial. The study results were presented during the 2023 annual meeting of the American Society of Clinical Oncology.

The post In Key Study, Servier Drug Delays Brain Cancer in Patients With Few Treatment Options appeared first on MedCity News.

A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six months—there were no detectable signs of the cancer. These early data presented at ASCO suggest that rectal cancer with a particular genetic signature might be treatable with this immunotherapy in lieu of the standard regimen of chemotherapy, radiation, and surgery.

The post GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers appeared first on MedCity News.

Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some of the news highlights from the biggest cancer conference of the year.

The post ASCO recap: Breast cancer breakthrough, Mirati’s moves, Arcellx ascends & more appeared first on MedCity News.

PMV Pharmaceuticals has its first clinical data showing that its lead therapeutic candidate can hit p53, a tumor-suppressing protein long thought to be undruggable. After reporting the preliminary data during ASCO, PMV said it plans to continue the Phase 1 study with the goal of advancing to Phase 2 early next year.

The post PMV’s ASCO data show signs of drugging ‘undruggable’ p53 protein across tumor types appeared first on MedCity News.

During the annual meeting of the American Society of Clinical Oncology, AstraZeneca and Daiichi Sankyo reported pivotal clinical trial data showing that their partnered cancer drug Enhertu can treat a group of patients previously thought to be out of reach for a targeted therapy. The results suggest use of this FDA-approved drug could significantly expand to more breast cancer patients.

The post AstraZeneca, Daiichi Sankyo have high hopes for drug that goes low in breast cancer appeared first on MedCity News.

The American Society of Clinical Oncology’s annual meeting begins this week, including the presentation of more than 2,800 abstracts. Amgen, Roche, and Sierra Oncology are among the companies with key presentations at this year’s gathering.

The post ASCO 2022 ahead: Clinical trial updates and data readouts to watch for appeared first on MedCity News.

The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.

The post ASCO 2021 recap: Lynparza’s lift, Grail goes on, LAG validation & more appeared first on MedCity News.

Cancer drug developer Merus has encouraging early results indicating its drug can address several different types of tumors characterized by NRG1, a rare gene fusion. The company believes the data could support a regulatory filing for the bispecific antibody drug.

The post Merus eyes tumor-agnostic path for cancer drug addressing rare genetic target appeared first on MedCity News.

Bristol Myers Squibb reported Phase 3 data that show its experimental cancer immunotherapy relatlimab, combined with the company’s blockbuster drug Opdivo, was better at stopping melanoma from progressing. BMS will present the data at the upcoming annual meeting of the American Society of Clinical Oncology.

The post Bristol Myers “dual immunotherapy” beats Opdivo alone in melanoma study appeared first on MedCity News.

In data at the ASCO meeting last week, Grail showed a 1 percent false-positive rate. While that number seems likely to go down, even such a low rate can make a significant difference for patients.

The post In blood tests for early cancer detection, low false-positive rates can be a big deal appeared first on MedCity News.

While isatuximab with Celgene’s Pomalyst beat Pomalyst with steroid alone, the bigger question is how it will fare on the market versus J&J’s Darzalex, which will likely soon be available as an easier-to-use subcutaneous injection.

The post Sanofi’s myeloma antibody shines at ASCO, but where will it fit into treatment? appeared first on MedCity News.

It remains unclear how many patients will relapse without the BCMA antigen, which would complicate their ability to use many CAR-T cell therapies later on. However, an expert said the drug’s safety could be a challenge.

The post Amgen’s bispecific antibody shows high response rate in multiple myeloma at ASCO appeared first on MedCity News.

Only time will tell if a larger Phase III study will confirm data on a few dozen patients, but the two-drug combination appears to produce a higher complete response rate than than an existing doublet combination, without the associated toxicity.

The post Nektar’s bempeg shows encouraging Phase II data in first-line melanoma with BMS’ Opdivo appeared first on MedCity News.

In an interview at the ASCO meeting, BeiGene chief adviser Eric Hedrick said the company is well-prepared for when it likely regains global rights to tislelizumab.

The post What’s the fate of BeiGene’s PD-1 inhibitor after Bristol-Myers Squibb’s buyout of Celgene? appeared first on MedCity News.

The company presented end-of-Phase I data from the trial, on KTE-X19, at the ASCO meeting in Chicago Saturday.

The post Gilead’s ZUMA-3 study shows continued efficacy, and results from tweaks to side effect management appeared first on MedCity News.

The company plans to present early data in a poster on Saturday showing no more than 1 percent of tests generated false-positive results across 12 solid tumor and blood cancers.

The post Grail’s liquid biopsy test shows high sensitivity in early cancer detection appeared first on MedCity News.

In a position statement, ASCO said PBM practices can result in medication dispensing errors, harm physicians’ ability to treat patients and drive up costs.

The post PBM practices harm care for cancer patients, oncology professional group says appeared first on MedCity News.

The legislation, which has drawn criticism from researchers, patient advocates and industry, would enable patients to request experimental drugs while bypassing the FDA.

The post Right-to-try bill passes in House, heads to president’s desk for signature appeared first on MedCity News.

Loxo’s data highlight growing industry interest in so-called “basket” trials and drugs that targeted to genetic markers instead of tumor types.

The post Loxo Oncology’s shares shoot up on early data slated for ASCO presentation appeared first on MedCity News.

Are portals delivering on their promise to engage patients? Or are these results too often a source of confusion and alarm for patients and the cause of more work for doctors because information is provided with little to no guidance?

The post Is the practice of delivering medical test results online through portals the best way to engage patients? appeared first on MedCity News.

“There is a real need to detect cancers that are small [less than 1 cm] before they metastasize. That would be the Holy Grail.”

The post ASCO: MRIs, contrast-enhanced mammography useful for small breast tumors appeared first on MedCity News.

The market leader in cancer panel gene testing flooded the zone at the annual meeting of the American Society of Clinical Oncology in Chicago.

The post Myriad touts studies at ASCO that back its transition toward panel testing for hereditary cancer appeared first on MedCity News.

The post Bayer gives $1M to ASCO’s big data effort appeared first on MedCity News.

The post ASCO launches big data effort to study cancer appeared first on MedCity News.